Keros Therapeutics, Inc.
KROS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001664710
In the last 90 days, Keros Therapeutics, Inc. insiders filed 1 open-market purchase and 4 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $198.6M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:56 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 4, 2026 | Feb 26, 2025 | Feb 28, 2024 | Mar 3, 2023 | Mar 9, 2022 |
| Revenue | $243.9M | $3.55M | $151.0K | $0 | $20.1M |
| Operating expenses | $176.5M | $214.4M | $170.1M | $114.8M | $76.5M |
| Research and development | $129.6M | $173.6M | $135.3M | $87.3M | $55.1M |
| Selling, general and administrative | $46.8M | $40.8M | $34.8M | $27.5M | $21.3M |
| Operating income | $67.6M | -$210.8M | -$169.9M | -$114.8M | -$56.4M |
| Interest expense | – | $0 | $0 | $1.00K | $4.00K |
| Income tax | $4.88M | $300.0K | $0 | $0 | $2.01M |
| Net income | $87.0M | -$187.4M | -$153.0M | -$104.7M | -$58.7M |
| EPS, basic | $2.34 | $-5.00 | $-5.20 | $-4.15 | $-2.52 |
| EPS, diluted | $2.30 | $-5.00 | $-5.20 | $-4.15 | $-2.52 |
| Weighted shares, basic | 37.2M | 37.4M | 29.4M | 25.2M | 23.3M |
| Weighted shares, diluted | 37.9M | 37.4M | 29.4M | 25.2M | 23.3M |
| Margins and growth | |||||
| Operating margin | 27.7% | -5939.0% | -112543.7% | – | -280.5% |
| Net margin | 35.7% | -5277.5% | -101319.2% | – | -292.3% |
| Revenue growth, year over year | +6,769.4% | +2,251.0% | – | −100.0% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 4, 2026 | Feb 26, 2025 | Feb 28, 2024 | Mar 3, 2023 | Mar 9, 2022 |
| Cash and equivalents | $287.4M | $559.9M | $331.1M | $279.0M | $230.0M |
| Accounts receivable | $3.57M | $2.74M | $143.0K | $0 | $18.0M |
| Total current assets | $315.4M | $588.9M | $347.3M | $285.8M | $251.4M |
| Property, plant and equipment | $4.30M | $4.24M | $4.13M | $2.02M | $1.33M |
| Total assets | $338.0M | $615.9M | $370.0M | $306.8M | $255.3M |
| Accounts payable | $1.97M | $4.60M | $5.45M | $3.34M | $3.65M |
| Total current liabilities | $20.4M | $27.4M | $24.4M | $16.5M | $11.8M |
| Total liabilities | $34.9M | $44.3M | $37.8M | $29.4M | $12.1M |
| Shareholders' equity | $303.1M | $571.6M | $332.2M | $277.4M | $243.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 4, 2026 | Feb 26, 2025 | Feb 28, 2024 | Mar 3, 2023 | Mar 9, 2022 |
| Operating cash flow | $107.5M | -$160.9M | -$124.5M | -$70.1M | -$62.1M |
| Capital expenditures | $1.55M | $1.93M | $2.46M | $1.24M | $1.02M |
| Free cash flow | $106.0M | -$162.8M | -$127.0M | -$71.3M | -$63.2M |
| Stock-based compensation | $28.7M | $34.9M | $28.8M | $18.7M | $11.7M |
| Share buybacks | $375.0M | – | – | – | – |
| Investing cash flow | -$1.55M | -$1.93M | -$2.46M | -$1.24M | -$1.02M |
| Financing cash flow | -$378.5M | $391.8M | $179.0M | $120.3M | $28.6M |
| Net change in cash | -$272.5M | $229.0M | $52.0M | $49.0M | -$34.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 11.8% | 982.3% | 19048.3% | – | 58.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 19.6M | −35.6% | SEC |
| Jul 27, 2026 | 19.8M | −51.2% | SEC |
| May 8, 2026 | 19.8M | −51.3% | SEC |
| Feb 27, 2026 | 19.7M | −51.4% | SEC |
| Oct 31, 2025 | 30.5M | −24.8% | SEC |
| Jul 31, 2025 | 40.6M | +8.2% | SEC |
| May 1, 2025 | 40.6M | +12.6% | SEC |
| Feb 20, 2025 | 40.6M | +12.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.